表紙
市場調查報告書
商品編碼
1067360

全球放射配體治療市場(2021-2031 年):按適應症、產品、生物標誌物、地區分類

Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast, 2021-2031

出版日期: | 出版商: BIS Research Inc. | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球放射配體治療市場預計將從 2020 年的 97.549 億美元增長到預測期內的 4.67% 的複合年增長率,並在 2031 年增長到 166.584 億美元。它一直在增長。

放射性配體治療劑,又稱具有抗腫瘤作用的放射性藥物,在過去十年中取得了長足的進步。一些治療方法已經被批准用於人類,但更多的正在臨床試驗中,將在未來兩到七年內出現在臨床環境中,為患者提供新的治療方法。可能會帶來合法的選擇。

本報告調查全球放射性配體治療市場,定義和概述市場,分析對市場增長、法律和監管環境、管道分析、市場規模趨勢和預測的各種影響因素,總結適應症、產品、生物標誌物、細分地區/主要國家、競爭環境、主要公司概況等。

目錄

第一章調查方法

第 2 章放射配體治療市場

  • 產品定義
  • 市場範圍
  • 市場概況
    • 市場定義
    • 放射配體治療的新用途
    • 市場足跡/增長潛力
    • COVID-19:對全球放射性配體治療市場的影響

第三章產業分析

  • 概覽
  • 監管審批渠道的挑戰
  • 法律場景
  • 美國法律要求和框架
  • 歐洲法律要求/框架
  • 亞太地區法律要求/框架

第4章管道分析

  • 管道分析
  • 臨床試驗設計
    • [Lu-177]-PNT2002
    • 凸輪 H2
    • [177Lu]-NeoB
    • PNT-2003
    • ITM-11
    • 177.Lu FAP-2286
    • FPI-1434
    • FPI-1966
    • 177Lu-DOTA-rosopatamab

第五章市場動態

  • 概覽
  • 影響分析
  • 市場促進因素
  • 市場製約因素
  • 市場機會

第6章競爭態勢

  • 概覽
  • 產品發布
  • 產品認證
  • 協同活動
  • 併購
  • 市場份額分析(按公司)

第 7 章全球放射性配體治療市場:按適應症

  • 概覽
  • 前列腺癌
  • 神經內分泌腫瘤(NET)
  • 其他

第 8 章全球放射性配體治療市場:按產品分類

  • 概覽
  • 獲批產品
    • 盧塔瑟拉
    • Zytiga
    • 克坦迪
    • Xofigo
  • 潛在管道

第 9 章全球放射性配體治療市場:按生物標誌物

  • 概覽
  • PSMA(前列腺特異性膜抗原)
  • Ki67 表達/分級
  • 細胞色素P45017A1抑製劑

第 10 章全球放射線治療市場:按地區

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 其他領域

第 11 章市場:競爭基準/公司簡介

  • 概覽
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals LLC.
  • Novartis International AG
  • POINT Biopharma Global Inc
  • Fusion Pharma
  • Clovis Oncology
  • Telix Pharmaceuticals
  • Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
  • Bayer AG
  • Molecular Partners

第12章 新興企業檔案

  • ITM Isotope Technologies Munich SE
  • Curium Pharma
  • Precirix
  • Radio Medix
目錄
Product Code: BHL1181SA

“Global Radioligand Therapy Market to Reach $16,658.4 Million by 2031.”

Market Report Coverage - Radioligand Therapy

Market Segmentation

  • Product (Approved Products and Potential Pipeline)
  • Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
  • Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - Japan, South Korea, Australia, and Rest-of-Asia-Pacific
  • Rest-of-the-World

Market Growth Drivers

  • Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
  • Strategic Initiatives by Key Market Players
  • Rise in Clinical Research Activity

Market Challenges

  • High Cost Associated with Treatment and Complex Reimbursement Processes
  • Increased Competition from Generics

Market Opportunities

  • Expanding Radiopharmaceutical Coverage
  • Role of Radioligand in Drug Discovery

Key Companies Profiled

Johnson & Johnson Services, Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, Novartis International AG, POINT Biopharma Global Inc, Fusion Pharma, Clovis Oncology, Telix Pharmaceuticals, Lantheus Holdings, Inc. (Progenics Pharmaceuticals), Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Curium Pharma, Precirix, Radio Medix.

Key Questions Answered in this Report:

  • How is radioligand therapy revolutionizing oncology?
  • What are the major market drivers, challenges, and opportunities in the global radioligand therapy market?
  • What are the underlying structures resulting in the emerging trends within the global radioligand therapy market?
  • How is the COVID-19 pandemic impacting the global radioligand therapy ecosystem?
  • What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
  • What are the key regulatory implications in developed and developing regions pertaining to the use of radioligand-targeted therapies?
  • What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
  • How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
    • Products (Approved Products and Potential Pipeline)
    • Indication (Prostate Cancer, Neuroendocrine Tumor (NETs), and Others)
    • Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
    • Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
  • What are the growth opportunities for the radioligand therapy companies in the region of their operation?
  • Who are the leading players with significant offerings in the global radioligand therapy market?
  • Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Radioligand therapeutics, also known as radiopharmaceuticals, which show antitumor effects, has seen rapid development over the past decade. Although some therapies are already approved for human use, many more are in the clinical trial and will enter clinical practice in the next 2-7 years, potentially introducing new therapeutic choices for patients. Despite this innovation, several challenges remain, including supply chain, logistics, regulatory issues, and education and training. The current market for radioligand therapy is majorly dominated by manufacturers such as Novartis AG, Pfizer Inc, Johnson & Johnson Services, Inc, Telix Pharmaceuticals, Lantheus Holdings Inc., (Progenics Pharmaceuticals), Molecular Partners AG, Clovis Oncology Inc., Fusion Pharma, Point Biopharma, Precirix, ITM Isotope Technologies Munich SE, Curium Pharma, and RadioMedix. The global radioligand therapy market was valued at $9,754.9 million in 2020 and is expected to reach $16,658.4 million by 2031, witnessing a CAGR of 4.67% during the forecast period 2021-2031.

Competitive Landscape

The global radioligand therapy market comprises well-established and newly emerging companies. Several companies are attempting to sustain their position in the market by launching new products and raising funds to develop new products for the innovation in radioligand therapy from different sample types. Key market players of the global radioligand therapy market witnessed product launch, product approval and business funding, and synergistic activities majorly during the period January 2018-February 2022. The inclination of companies toward product launches and product approval suggests that the companies are involved in continuously bringing new products to the market to radioligand therapy, which is primarily attributed to a rising prevalence of cancer, rising clinical research activity, and rising key players' initiatives are driving the market.

Table of Contents

1 Research Methodology

  • 1.1 Radioligand Therapy: Research Methodology
  • 1.2 Primary Data Sources
  • 1.3 Secondary Data Sources
  • 1.4 Market Estimation Model
  • 1.5 Criteria for Company Profiling

2 Radioligand Therapy Market

  • 2.1 Product Definition
    • 2.1.1 Inclusion and Exclusion
  • 2.2 Market Scope
    • 2.2.1 Scope of the Study
    • 2.2.2 Key Questions Answered in the Report
  • 2.3 Market Overview
    • 2.3.1 Market Definition
    • 2.3.2 Emerging Applications of Radioligand Therapy
      • 2.3.2.1 Neuroendocrine Neoplasms
      • 2.3.2.2 Prostate Cancer
      • 2.3.2.3 Non-Cancerous Condition
    • 2.3.3 Market Footprint and Growth Potential
    • 2.3.4 COVID-19 Impact on Global Radioligand Therapy Market
      • 2.3.4.1 Impact on Radioligand Therapy
      • 2.3.4.2 Clinical Trial Disruptions and Resumptions

3 Industry Analysis

  • 3.1 Overview
  • 3.2 Challenges in Radioligand Therapy Regulatory Approval Pathway
  • 3.3 Regulatory Scenario of Radioligand Therapy
  • 3.4 Legal Requirements and Frameworks in the U.S.
    • 3.4.1 Clinical Trial Authorization
    • 3.4.2 Marketing Authorization
    • 3.4.3 U.S. FDA Guidelines for NDA Submission
    • 3.4.4 Post-Authorization Regulations
  • 3.5 Legal Requirements and Frameworks in Europe
    • 3.5.1 EMA Drug License Application Process
    • 3.5.2 Centralized Procedure
    • 3.5.3 Decentralized Procedure
    • 3.5.4 Mutual-Recognition Procedure
    • 3.5.5 National Procedure
  • 3.6 Legal Requirements and Frameworks in Asia-Pacific
    • 3.6.1 Legal Requirements and Frameworks in Japan

4 Pipeline Analysis

  • 4.1 Radioligand Therapy Pipeline Analysis
  • 4.2 Radioligand Therapy Clinical Trial Design
    • 4.2.1 [Lu-177]-PNT2002
      • 4.2.1.1 Product Profile
      • 4.2.1.2 [Lu-177]-PNT2002 Phase III Study Design
      • 4.2.1.3 [Lu-177]-PNT2002 Efficacy, Safety, and Tolerability (Phase II)
      • 4.2.1.4 177Lu-PNT2002 Pharmacokinetics and Pharmacodynamics Profile (Phase I)
    • 4.2.2 CAM H2
      • 4.2.2.1 Product Profile
      • 4.2.2.2 CAM H2 Preclinical Study Design
      • 4.2.2.3 CAM H2 Phase I/IIa Clinical Study Design
    • 4.2.3 [177Lu]-NeoB
      • 4.2.3.1 Product Profile
      • 4.2.3.2 (177Lu)-NeoB Preclinical Studies
      • 4.2.3.3 (177Lu)-NeoB Phase I/II Clinical Study Design
    • 4.2.4 PNT-2003
      • 4.2.4.1 Product Profile
      • 4.2.4.2 PNT 2003 Ongoing Phase III Clinical Study Design
    • 4.2.5 ITM-11
      • 4.2.5.1 Product Profile
      • 4.2.5.2 ITM-11 Preclinical Proof-of-Concept Studies
      • 4.2.5.3 ITM-11 Phase III Clinical Trial Design
    • 4.2.6 177.Lu FAP-2286
      • 4.2.6.1 Product Profile
      • 4.2.6.2 177.Lu FAP, 2286 Preclinical Study Summary
      • 4.2.6.3 177Lu-FAP-2286 Phase I/IIa Clinical Study Design
    • 4.2.7 FPI-1434
      • 4.2.7.1 Product Profile
      • 4.2.7.2 FPI-1434 Preclinical Study Summary
      • 4.2.7.3 FPI-1434 Phase I/IIa Clinical Study Design
    • 4.2.8 FPI-1966
      • 4.2.8.1 Product Profile
      • 4.2.8.2 FPI-1966 Preclinical Study Summary
    • 4.2.9 177Lu-DOTA-rosopatamab
      • 4.2.9.1 Product Profile
      • 4.2.9.2 TLX591 (177Lu-DOTA-rosopatamab) Ongoing Phase III Clinical Study Design

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
  • 5.3 Market Drivers
    • 5.3.1 Radioligand Therapy Demand Inclined by Rising Prevalence of Cancer
    • 5.3.2 Strategic Initiatives by Key Market Players
    • 5.3.3 Rise in Clinical Research Activity
  • 5.4 Market Restraints
    • 5.4.1 High Cost Associated with Treatment and Complex Reimbursement Processes
    • 5.4.2 Increased Competition from Generics
  • 5.5 Market Opportunities
    • 5.5.1 Expanding Radiopharmaceutical Coverage
    • 5.5.2 Role of Radioligand in Drug Discovery

6 Competitive Landscape

  • 6.1 Overview
  • 6.2 Product Launch
  • 6.3 Product Approvals
  • 6.4 Synergistic Activities
  • 6.5 Mergers and Acquisitions
  • 6.6 Market Share Analysis (by Company), 2020

7 Global Radioligand Therapy Market, Indication, $Million, 2020-2031

  • 7.1 Overview
  • 7.2 Prostate Cancer
  • 7.3 Neuroendocrine Tumor (NETs)
  • 7.4 Other

8 Global Radioligand Therapy Market, Products, $Million, 2020-2031

  • 8.1 Overview
  • 8.2 Approved Products
    • 8.2.1 Lutathera
    • 8.2.2 Zytiga
    • 8.2.3 Xtandi
    • 8.2.4 Xofigo
  • 8.3 Potential Pipeline

9 Global Radioligand Therapy Market, Biomarker, $Million, 2020-2031

  • 9.1 Overview
  • 9.2 Prostate-Specific Membrane Antigen
  • 9.3 Ki 67 Expression and Grading
  • 9.4 Cytochrome P450 17A1 Inhibitor

10 Global Radioligand Therapy Market, Region, $Million, 2020-2031

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 France
    • 10.3.3 U.K.
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest-of-Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 South Korea
    • 10.4.3 Australia
    • 10.4.4 Rest-of-Asia-Pacific (RoAPAC)
  • 10.5 Rest-of-the-World (RoW)

11 Markets - Competitive Benchmarking & Company Profiles

  • 11.1 Overview
  • 11.2 Johnson & Johnson Services, Inc.
    • 11.2.1 Company Overview
    • 11.2.2 Role of Johnson & Johnson Services, Inc. in the Global Radioligand Therapy Market
    • 11.2.3 Product ASP (by Region)
    • 11.2.4 Key Competitors of Company
    • 11.2.5 Financials
    • 11.2.6 Key Insights About the Financial Health of the Company
    • 11.2.7 SWOT Analysis
  • 11.3 Pfizer Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Role of Pfizer Inc. in the Global Radioligand Therapy Market
    • 11.3.3 Product ASP (by Region)
    • 11.3.4 Key Competitors of Company
    • 11.3.5 Financials
    • 11.3.6 Key Insights About Financial Health of the Company
    • 11.3.7 Business Strategies
      • 11.3.7.1 Product Approval
    • 11.3.8 SWOT Analysis
  • 11.4 Amneal Pharmaceuticals LLC.
    • 11.4.1 Company Overview
    • 11.4.2 Role of Amneal Pharmaceuticals LLC. in the Global Radioligand Therapy Market
    • 11.4.3 Key Competitors of Company
    • 11.4.4 Financials
    • 11.4.5 Key Insights About Financial Health of the Company
    • 11.4.6 Business Strategies
      • 11.4.6.1 Product Launch
    • 11.4.7 SWOT Analysis
  • 11.5 Novartis International AG
    • 11.5.1 Company Overview
    • 11.5.2 Role of Novartis International AG in the Global Radioligand Therapy Market
    • 11.5.3 Product ASP (by Region)
    • 11.5.4 Key Competitors of Company
    • 11.5.5 Financials
    • 11.5.6 Key Insights About Financial Health of the Company
    • 11.5.7 Corporate Strategies
      • 11.5.7.1 Mergers and Acquisitions
      • 11.5.7.2 Synergistic Activities
      • 11.5.7.3 Business Expansion and Funding
    • 11.5.8 Business Strategies
      • 11.5.8.1 Product Launches and Approval
    • 11.5.9 SWOT Analysis
  • 11.6 POINT Biopharma Global Inc
    • 11.6.1 Company Overview
    • 11.6.2 Role of POINT Biopharma Global Inc in the Global Radioligand Therapy Market
    • 11.6.3 Key Competitors of Company
    • 11.6.4 Corporate Strategies
    • 11.6.5 SWOT Analysis
  • 11.7 Fusion Pharma
    • 11.7.1 Company Overview
    • 11.7.2 Role of Fusion Pharma in the Global Radioligand Therapy Market
    • 11.7.3 Key Competitors of Company
    • 11.7.4 Financials
    • 11.7.5 Key Insights About the Financial Health of the Company
    • 11.7.6 Corporate Strategies
      • 11.7.6.1 Synergistic Activities
    • 11.7.7 SWOT Analysis
  • 11.8 Clovis Oncology
    • 11.8.1 Company Overview
    • 11.8.2 Role of Clovis Oncology in the Global Radioligand Therapy Market
    • 11.8.3 Key Competitors of Company
    • 11.8.4 Financials
    • 11.8.5 Key Insights About the Financial Health of the Company
    • 11.8.6 Corporate Strategies
      • 11.8.6.1 Mergers and Acquisitions
    • 11.8.7 SWOT Analysis
  • 11.9 Telix Pharmaceuticals
    • 11.9.1 Company Overview
    • 11.9.2 Role of Telix Pharmaceuticals in the Global Radioligand Therapy Market
    • 11.9.3 Key Competitors of Company
    • 11.9.4 Financials
    • 11.9.5 Key Insights About the Financial Health of the Company
    • 11.9.6 Corporate Strategies
      • 11.9.6.1 Mergers and Acquisitions
      • 11.9.6.2 Synergistic Activities
    • 11.9.7 SWOT Analysis
  • 11.1 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
    • 11.10.1 Company Overview
    • 11.10.2 Role of Lantheus Holdings Inc., (Progenics Pharmaceuticals) in the Global Radioligand Therapy Market
    • 11.10.3 Key Competitors of Company
    • 11.10.4 Financials
    • 11.10.5 Key Insights About the Financial Health of the Company
    • 11.10.6 Corporate Strategies
      • 11.10.6.1 Mergers and Acquisitions
    • 11.10.7 SWOT Analysis
  • 11.11 Bayer AG
    • 11.11.1 Company Overview
    • 11.11.2 Role of Bayer AG in the Global Radioligand Therapy Market
    • 11.11.3 Product ASP (by Region)
    • 11.11.4 Key Competitors of Company
    • 11.11.5 Financials
    • 11.11.6 Key Insights About the Financial Health of the Company
    • 11.11.7 Corporate Strategies
      • 11.11.7.1 Mergers and Acquisitions
      • 11.11.7.2 Product Approval
    • 11.11.8 SWOT Analysis
  • 11.12 Molecular Partners
    • 11.12.1 Company Overview
    • 11.12.2 Role of Molecular Partners in the Global Radioligand Therapy Market
    • 11.12.3 Key Competitors of Company
    • 11.12.4 SWOT Analysis

12 Emerging Company Profiles.

  • 12.1 ITM Isotope Technologies Munich SE
    • 12.1.1 Company Overview
    • 12.1.2 Role of ITM Isotope Technologies Munich SE in the Global Radioligand Therapy Market
    • 12.1.3 Key Competitors of Company
    • 12.1.4 SWOT Analysis
  • 12.2 Curium Pharma
    • 12.2.1 Company Overview
    • 12.2.2 Role of Curium Pharma. in the Global Radioligand Therapy Market
    • 12.2.3 Key Competitors of Company
    • 12.2.4 SWOT Analysis
  • 12.3 Precirix
    • 12.3.1 Company Overview
    • 12.3.2 Role of Precirix in the Global Radioligand Therapy Market
    • 12.3.3 Key Competitors of Company
    • 12.3.4 SWOT Analysis
  • 12.4 Radio Medix
    • 12.4.1 Company Overview
    • 12.4.2 Role of Radio Medix in the Global Radioligand Therapy Market
    • 12.4.3 Key Competitors of Company
    • 12.4.4 SWOT Analysis

List of Figures

  • Figure 1: Global Cancer Burden, 2020
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Radioligand Therapy Market
  • Figure 3: Revenue Contribution of Different Segments, 2020, 2029, and 2031
  • Figure 4: Revenue Contribution of Different Segments, 2020, 2021, and 2031
  • Figure 5: Revenue Contribution of Different Segments, 2020, 2021, and 2031
  • Figure 6: Global Radioligand Therapy Market (by Region), $Million, 2023-2031
  • Figure 7: Global Radioligand Therapy Methodology
  • Figure 8: Primary Research Methodology
  • Figure 9: Epidemiology-Based Approach
  • Figure 10: Global Radioligand Therapy Market Segmentation
  • Figure 11: Global Radioligand Therapy Market, $Million, 2020-2031
  • Figure 12: Clinical Trial Authorization for Radioligand Therapy in the U.S.
  • Figure 13: Steps for Obtaining Marketing Authorization
  • Figure 14: U.S. FDA Review Timeline
  • Figure 15: EMA Review Timeline
  • Figure 16: Radioligand Therapy Global Clinical Trials (by Phase), 2021
  • Figure 17: Radioligand Therapy Global Clinical Trials 2021
  • Figure 18: 177Lu-PSMA-617 (RA101495) Mechanism of Action
  • Figure 19: [Lu-177]-PNT2002 Phase III Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer
  • Figure 20: 177Lu-PNT2002 Phase II Clinical Trial Design for Metastatic Castration-Resistant Prostate Cancer
  • Figure 21: 177Lu-PNT2002 PK/PD Profile Results
  • Figure 22: CAM H2 Phase I Portion Clinical Study
  • Figure 23: Solid Tumors with Overexpression
  • Figure 24: (177Lu)-NeoB Preclinical Studies Framework
  • Figure 25: (177Lu)-NeoB Phase I Portion Clinical Study
  • Figure 26: Phase III clinical Design for PNT-2003
  • Figure 27: Results from ITM-11 Phase III Clinical Trial
  • Figure 28: 177Lu-FAP-2286 I/IIa Portion Clinical Study
  • Figure 29: FPI-1434 I/IIa Portion Clinical Study
  • Figure 30: Phase III clinical Design for PNT-2003
  • Figure 31: Global Cancer Burden, 2020
  • Figure 32: Share of Key Developments, January 2018-February 2022
  • Figure 33: Share of Product Approvals (by Company), January 2018-November 2021
  • Figure 34: Share of Synergistic Activities (by Company), January 2018-February 2022
  • Figure 35: Share of Mergers and Acquisitions (by Company), January 2018-February 2022
  • Figure 36: Market Share Analysis of Global Radio Ligand Therapy Market (by Company), 2020
  • Figure 37: Revenue Contribution of Different Segments, 2020, 2039, and 2031
  • Figure 38: Global Radioligand Therapy Market (Prostate Cancer), $Million, 2020-2031
  • Figure 39: Global Radioligand Therapy Market (Neuroendocrine Tumors), $Million, 2025-2031
  • Figure 40: Global Radioligand Therapy Market (Others), $Million, 2029-2031
  • Figure 41: Global Radioligand Therapy Market Segmentation (by Product)
  • Figure 42: Global Radioligand Therapy Market (Approved Products), $Million, 2020-2031
  • Figure 43: Global Radioligand Therapy Market (Lutathera), $Million, 2020-2031
  • Figure 44: Global Radioligand Therapy Market (Zytiga), $Million, 2020-2031
  • Figure 45: Global Radioligand Therapy Market (Xtandi), $Million, 2020-2031
  • Figure 46: Global Radioligand Therapy Market (Xofigo), $Million, 2020-2031
  • Figure 47: Global Radioligand Therapy Market (Potential Pipeline), $Million, 2024-2031
  • Figure 48: Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 3)), $Million, 2024-2031
  • Figure 49: Global Radioligand Therapy Market (by Potential Pipeline Drugs (Phase 2)), $Million, 2029-2031
  • Figure 50: Global Radioligand Therapy Market (by Biomarker)
  • Figure 51: Global Radioligand Therapy Market (by Biomarker), $Million, 2020 and 2031
  • Figure 52: Global Radioligand Therapy Market (Prostate-Specific Membrane Antigen), $Million, 2020-2031
  • Figure 53: Global Radioligand Therapy Market (Ki 67 Expression and Grading), $Million, 2020-2031
  • Figure 54: Global Radioligand Therapy Market (Cytochrome P450 17A1 Inhibitor), $Million, 2020-2031
  • Figure 55: Global Radioligand Therapy Market Snapshot (by Region), $Million, 2020-2031
  • Figure 56: Global Radioligand Therapy Market (by Region), $Million, 2020-2031
  • Figure 57: North America Radioligand Therapy Market, $Million, 2020-2031
  • Figure 58: North America: Market Dynamics
  • Figure 59: North America Radioligand Therapy Market (by Country), $Million, 2020-2031
  • Figure 60: U.S. Radioligand Therapy Market, $Million, 2020-2031
  • Figure 61: Canada Radioligand Therapy Market, $Million, 2020-2031
  • Figure 62: Europe Radioligand Therapy Market, $Million, 2020-2031
  • Figure 63: Europe: Market Dynamics
  • Figure 64: Europe Radioligand Therapy Market (by Country), $Million, 2020-2031
  • Figure 65: Germany Radioligand Therapy Market, $Million, 2020-2031
  • Figure 66: France Radioligand Therapy Market, $Million, 2020-2031
  • Figure 67: U.K. Radioligand Therapy Market, $Million, 2020-2031
  • Figure 68: Italy Radioligand Therapy Market, $Million, 2020-2031
  • Figure 69: Spain Radioligand Therapy Market, $Million, 2020-2031
  • Figure 70: Rest-of Europe Radioligand Therapy Market, $Million, 2020-2031
  • Figure 71: Asia-Pacific Radioligand Therapy Market, $Million, 2020-2031
  • Figure 72: Asia-Pacific: Market Dynamics
  • Figure 73: APAC Radioligand Therapy Market (by Country), $Million, 2020-2031
  • Figure 74: Japan Radioligand Therapy Market, $Million, 2020-2031
  • Figure 75: South Korea Radioligand Therapy Market, $Million, 2020-2031
  • Figure 76: Australia Radioligand Therapy Market, $Million, 2020-2031
  • Figure 77: RoAPAC Radioligand Therapy Market, $Million, 2020-2031
  • Figure 78: Rest-of-the-World (RoW) Radioligand Therapy Market, $Million, 2020-2031
  • Figure 79: Total Number of Companies Profiled
  • Figure 80: Johnson & Johnson Services, Inc.: Product Portfolio
  • Figure 81: Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2018-2020
  • Figure 82: Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2018-2020
  • Figure 83: Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 84: Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 85: Johnson & Johnson Services, Inc.: SWOT Analysis
  • Figure 86: Pfizer Inc.: Commercialized Therapy
  • Figure 87: Pfizer Inc.: Overall Financials, $Million, 2018-2020
  • Figure 88: Pfizer Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 89: Pfizer Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 90: Pfizer Inc.: SWOT Analysis
  • Figure 91: Amneal Pharmaceuticals LLC.: Commercialized Therapy
  • Figure 92: Amneal Pharmaceuticals LLC.: Overall Financials, $Million, 2018-2020
  • Figure 93: Amneal Pharmaceuticals LLC.: Revenue (by Segment), $Million, 2018-2020
  • Figure 94: Amneal Pharmaceuticals LLC.: R&D Expenditure, $Million, 2018-2020
  • Figure 95: Amneal Pharmaceuticals.: SWOT Analysis
  • Figure 96: Novartis International AG: Commercialized Therapy
  • Figure 97: Novartis International AG: Pre-Clinical and Clinical Assets
  • Figure 98: Novartis International AG: Overall Financials, $Million, 2018-2020
  • Figure 99: Novartis International AG: Revenue (by Segment), $Million, 2018-2020
  • Figure 100: Novartis International AG: Revenue (by Region), $Million, 2018-2020
  • Figure 101: Novartis International AG: R&D Expenditure, $Million, 2018-2020
  • Figure 102: Novartis International AG: SWOT Analysis
  • Figure 103: POINT Biopharma Global Inc.: Pipeline Therapy
  • Figure 104: POINT Biopharma Global Inc.: SWOT Analysis
  • Figure 105: Fusion Pharma: Pipeline Portfolio
  • Figure 106: Fusion Pharma: Overall Financials, $Million, 2019-2020
  • Figure 107: Fusion Pharma: R&D Expenditure, $Million, 2019-2020
  • Figure 108: Fusion Pharma: SWOT Analysis
  • Figure 109: Clovis Oncology.: Pipeline Portfolio
  • Figure 110: Clovis Oncology.: Overall Financials, $Million, 2018-2020
  • Figure 111: Clovis Oncology.: Revenue (by Region), $Million, 2019-2020
  • Figure 112: Clovis Oncology.: R&D Expenditure, $Million, 2018-2020
  • Figure 113: Clovis Oncology.: SWOT Analysis
  • Figure 114: Telix Pharmaceuticals: Product Portfolio
  • Figure 115: Telix Pharmaceuticals: Overall Financials, $Million, 2018-2020
  • Figure 116: Telix Pharmaceuticals: R&D Expenditure, $Million, 2018-2020
  • Figure 117: Telix Pharmaceuticals.: SWOT Analysis
  • Figure 118: Lantheus Holdings Inc., (Progenics Pharmaceuticals): Pipeline Portfolio
  • Figure 119: Lantheus Holdings Inc. (Progenics Pharmaceuticals): Overall Financials, $Million, 2018-2020
  • Figure 120: Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Segment), $Million, 2019 and 2020
  • Figure 121: Lantheus Holdings Inc. (Progenics Pharmaceuticals): Revenue (by Region), $Million, 2018-2020
  • Figure 122: Lantheus Holdings Inc. (Progenics Pharmaceuticals): R&D Expenditure, $Million, 2018-2020
  • Figure 123: Lantheus Holdings Inc. (Progenics Pharmaceuticals): SWOT Analysis
  • Figure 124: Bayer AG.: Product Portfolio
  • Figure 125: Bayer AG.: Overall Financials, $Million, 2018-2020
  • Figure 126: Bayer AG: Revenue (by Region), $Million, 2018-2020
  • Figure 127: Bayer AG.: R&D Expenditure, $Million, 2018-2020
  • Figure 128: Bayer AG.: SWOT Analysis
  • Figure 129: Molecular Partners.: Product Portfolio
  • Figure 130: Molecular Partners.: SWOT Analysis
  • Figure 131: ITM Isotope Technologies Munich SE: Product Portfolio
  • Figure 132: ITM Isotope Technologies Munich SE: SWOT Analysis
  • Figure 133: Curium Pharma.: Product Portfolio
  • Figure 134: Curium Pharma: SWOT Analysis
  • Figure 135: Precirix: Product Portfolio
  • Figure 136: Precirix: SWOT Analysis
  • Figure 137: Radiomedix: Product Portfolio
  • Figure 138: RadioMedix: SWOT Analysis

List of Tables

  • Table 1: Regulatory Scenario of Radioligand Therapy
  • Table 2: Emerging Radioligand Therapy Pipeline
  • Table 3: Likert Scale
  • Table 4: Impact Analysis of Market Drivers
  • Table 5: Impact Analysis of Market Restraints
  • Table 6: Lutathera ASP by Region
  • Table 7: Xtandi: Indications